Terms: = Skin cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1
5372 results:
1. RICTOR/mTORC2 downregulation in braf
Ponzone L; Audrito V; Landi C; Moiso E; Levra Levron C; Ferrua S; Savino A; Vitale N; Gasparrini M; Avalle L; Vantaggiato L; Shaba E; Tassone B; Saoncella S; Orso F; Viavattene D; Marina E; Fiorilla I; Burrone G; Abili Y; Altruda F; Bini L; Deaglio S; Defilippi P; Menga A; Poli V; Porporato PE; Provero P; Raffaelli N; Riganti C; Taverna D; Cavallo F; Calautti E
Mol Cancer; 2024 May; 23(1):105. PubMed ID: 38755661
[TBL] [Abstract] [Full Text] [Related]
2. Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
Gargett T; Truong NTH; Gardam B; Yu W; Ebert LM; Johnson A; Yeo ECF; Wittwer NL; Tapia Rico G; Logan J; Sivaloganathan P; Collis M; Ruszkiewicz A; Brown MP
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38754916
[TBL] [Abstract] [Full Text] [Related]
3. braf-Mutated Melanoma Journey in Latin America: Expert Recommendations From Diagnosis to Treatment.
Bravo-Garzón MA; Bornstein-Quevedo L; Camargo VP; Sanku G; Jansen AM; Macedo MP; Rico-Restrepo M; Chacón M
Cancer Control; 2024; 31():10732748241251572. PubMed ID: 38751033
[TBL] [Abstract] [Full Text] [Related]
4. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
[TBL] [Abstract] [Full Text] [Related]
5. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
[TBL] [Abstract] [Full Text] [Related]
6. [Dramatic response to encorafenib plus binimetinib in a patient with leukemoid reaction from metastatic melanoma.].
Cerro M; Maccallini MT; Russillo M
Recenti Prog Med; 2024 May; 115(5):13e-16e. PubMed ID: 38708541
[TBL] [Abstract] [Full Text] [Related]
7. [Advanced melanoma with low-burden and low-risk disease: a clinical case.].
Bersanelli M
Recenti Prog Med; 2024 May; 115(5):7e-12e. PubMed ID: 38708540
[TBL] [Abstract] [Full Text] [Related]
8. Clinical, Morphological and Molecular Features of Spitz tumors.
Donati M; Mansour B; Hagstrom M; Gerami P; Kazakov DV
Cesk Patol; 2024; 60(1):35-48. PubMed ID: 38697826
[TBL] [Abstract] [Full Text] [Related]
9. MOG Antibody-Associated Disease in the Setting of Metastatic Melanoma Complicated by Immune Checkpoint Inhibitor Use.
Syc-Mazurek SB; Zhao-Fleming H; Guo Y; Tisavipat N; Chen JJ; Zekeridou A; Kournoutas I; Orme JJ; Block MS; Lucchinetti CF; Mustafa R; Flanagan EP
Neurol Neuroimmunol Neuroinflamm; 2024 Jul; 11(4):e200249. PubMed ID: 38696737
[TBL] [Abstract] [Full Text] [Related]
10. Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi).
Parums DV
Med Sci Monit; 2024 May; 30():e944927. PubMed ID: 38689550
[TBL] [Abstract] [Full Text] [Related]
11. Curcumin Alone and Combined With PI3K Inhibitors Elicits Positive Effects on Oropharyngeal cancer Cell Lines Regardless of HPV Status.
Lukoceviciute M; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
Anticancer Res; 2024 May; 44(5):1863-1876. PubMed ID: 38677772
[TBL] [Abstract] [Full Text] [Related]
12. The immune response-related genomic alterations in patients with malignant melanoma.
Li L; Xiang T; Li X
Medicine (Baltimore); 2024 Apr; 103(17):e37966. PubMed ID: 38669390
[TBL] [Abstract] [Full Text] [Related]
13. The involvement of RIPK4 in TNF-α-stimulated IL-6 and IL-8 production by melanoma cells.
Madej E; Lisek A; Brożyna AA; Cierniak A; Wronski N; Deptula M; Wardowska A; Wolnicka-Glubisz A
J Cancer Res Clin Oncol; 2024 Apr; 150(4):209. PubMed ID: 38656555
[TBL] [Abstract] [Full Text] [Related]
14. Tumor-targeted therapy with braf-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract] [Full Text] [Related]
15. Lifileucel: First Approval.
Keam SJ
Mol Diagn Ther; 2024 May; 28(3):339-344. PubMed ID: 38625642
[TBL] [Abstract] [Full Text] [Related]
16. Overcoming braf and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation.
Park S; Ryu WJ; Kim TY; Hwang Y; Han HJ; Lee JD; Kim GM; Sohn J; Kim SK; Kim MH; Kim J
Exp Mol Med; 2024 Apr; 56(4):987-1000. PubMed ID: 38622197
[TBL] [Abstract] [Full Text] [Related]
17. Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort.
Ichimura N; Urata Y; Kobayashi T; Hibi H
Oral Oncol; 2024 May; 152():106807. PubMed ID: 38615585
[TBL] [Abstract] [Full Text] [Related]
18. Genomic deletions explain the generation of alternative braf isoforms conferring resistance to MAPK inhibitors in melanoma.
Aya F; Lanuza-Gracia P; González-Pérez A; Bonnal S; Mancini E; López-Bigas N; Arance A; Valcárcel J
Cell Rep; 2024 Apr; 43(4):114048. PubMed ID: 38614086
[TBL] [Abstract] [Full Text] [Related]
19. Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma.
Hennemann A; Puzenat E; Decreuse M; Vuillier F; Nardin C; Aubin F
Melanoma Res; 2024 Jun; 34(3):280-282. PubMed ID: 38602773
[TBL] [Abstract] [Full Text] [Related]
20. Combined therapy of dabrafenib and an anti-HER2 antibody-drug conjugate for advanced braf-mutant melanoma.
Li W; Zheng C; Xu X; Xia Y; Zhang K; Huang A; Zhang X; Zheng Y; Chen G; Zhang S
Cell Mol Biol Lett; 2024 Apr; 29(1):50. PubMed ID: 38594618
[TBL] [Abstract] [Full Text] [Related]
[Next]
